JP2022132706A - Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same - Google Patents
Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same Download PDFInfo
- Publication number
- JP2022132706A JP2022132706A JP2021024790A JP2021024790A JP2022132706A JP 2022132706 A JP2022132706 A JP 2022132706A JP 2021024790 A JP2021024790 A JP 2021024790A JP 2021024790 A JP2021024790 A JP 2021024790A JP 2022132706 A JP2022132706 A JP 2022132706A
- Authority
- JP
- Japan
- Prior art keywords
- igg
- fucosylated
- bound
- fucose
- acetylglucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 39
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 39
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 210000002966 serum Anatomy 0.000 claims abstract description 49
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960001230 asparagine Drugs 0.000 claims abstract description 21
- 235000009582 asparagine Nutrition 0.000 claims abstract description 21
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
- 235000000346 sugar Nutrition 0.000 claims description 64
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 34
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 33
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 33
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 28
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 28
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 27
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 27
- 229930182830 galactose Natural products 0.000 claims description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 9
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 8
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 8
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 8
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical group O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 claims description 7
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 6
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 6
- 102000002068 Glycopeptides Human genes 0.000 claims description 4
- 108010015899 Glycopeptides Proteins 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 208000000185 Localized scleroderma Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 230000005784 autoimmunity Effects 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 229940105778 coagulation factor viii Drugs 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 206010059284 Epidermal necrosis Diseases 0.000 claims 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 claims 1
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 229940027941 immunoglobulin g Drugs 0.000 description 116
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 9
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- -1 etc.) Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- 229930182474 N-glycoside Natural products 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005918 transglycosylation reaction Methods 0.000 description 3
- BNGPVKSKKYIJCR-UHFFFAOYSA-N 2-chloro-1,3-dimethylimidazolidine;hydrochloride Chemical compound [Cl-].CN1CC[NH+](C)C1Cl BNGPVKSKKYIJCR-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- KMJYGLJORYOCJF-OABTZWTBSA-L disodium;5-acetamido-2-[[6-[5-acetamido-6-[2-[[6-[5-acetamido-6-[5-acetamido-6-[[(3s)-4-[[(2s)-6-amino-1-[[(1s,2r)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]amino]-3-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propano Chemical compound [Na+].[Na+].OC1C(NC(C)=O)C(NC(=O)C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)OC(CO)C1OC1C(NC(C)=O)C(O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(OC4C(C(O)C(O)C(COC5(OC(C(NC(C)=O)C(O)C5)[C@H](O)[C@H](O)CO)C([O-])=O)O4)O)C(CO)O3)NC(C)=O)C(O)C(COC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(OC4C(C(O)C(O)C(COC5(OC(C(NC(C)=O)C(O)C5)[C@H](O)[C@H](O)CO)C([O-])=O)O4)O)C(CO)O3)NC(C)=O)O2)O)C(CO)O1 KMJYGLJORYOCJF-OABTZWTBSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229950007699 mogamulizumab Drugs 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 108700004049 glycosylated serum Proteins 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本発明は、抗炎症性非フコシル化免疫グロブリン製剤及びその製造方法に関する。 The present invention relates to anti-inflammatory non-fucosylated immunoglobulin formulations and methods for their production.
IVIGは川崎病、特発性血小板減少性紫斑病、ギラン・バレー症候群などの自己免疫疾患に対する数少ない治療選択肢の一つである。IVIGはIgGを数千の健常人の血漿から分画し、精製、濃縮されて製造される。治療効果はIgG-Fc 部分にあり(非特許文献１、２)、IgG-FcのAsn297結合糖鎖が必要であると報告されているが(非特許文献２)、抗炎症作用の機序は明らかではない。IgG-Fcの糖鎖は、Fcγ受容体や補体活性化などIgGのエフェクター機能の発現に必須であり、糖鎖の除去により抗体依存性細胞傷害作用(ADCC)や補体依存性細胞傷害作用等が大きく損なわれる(非特許文献３)。IgG-Fc糖鎖は、7糖からなるコア構造にフコース、ガラクトース、シアル酸等が結合し、高度な不均一性を示す(図1)。これらの非還元末端に結合する単糖は、様々な生物活性との関連が報告されている(非特許文献４)。
IVIG is one of the few treatment options for autoimmune diseases such as Kawasaki disease, idiopathic thrombocytopenic purpura, and Guillain-Barre syndrome. IVIG is manufactured by fractionating, purifying, and concentrating IgG from the plasma of thousands of healthy individuals. It has been reported that the therapeutic effect resides in the IgG-Fc portion (
フコース除去はADCCを100倍程度増強することが示され(非特許文献５，６)、既に非フコシル化モノクローナル抗体(Mogamulizumab, Obinutuzumab)は成人T 細胞白血病やCD20陽性濾胞性リンパ腫に対して臨床応用されている。自己免疫疾患に抗炎症効果を示すIVIGの有効成分の同定やその作用機序の解明は、今後も需要が増大するIVIGに代わる新規抗体医薬の開発のためにも必要である。
Fucose removal has been shown to enhance ADCC about 100 times (Non-Patent
本発明はかかる問題点に鑑みてなされたものであって、自己免疫疾患等の炎症性疾患に対する新しい治療薬を提供することを目的とする。 The present invention has been made in view of such problems, and an object of the present invention is to provide a new therapeutic agent for inflammatory diseases such as autoimmune diseases.
本発明にかかる抗炎症性非フコシル化免疫グロブリン製剤は、包含されるIgG抗体が、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体からなることを特徴とする。ここでGはガラクトース、NはN-アセチルグルコサミン、Mはマンノースである。 The anti-inflammatory non-fucosylated immunoglobulin preparation of the present invention is characterized in that the IgG antibodies to be included consist of human serum IgG antibodies in which the sugar chain shown below is linked to asparagine 297 (Asn297) of the Fc portion. Characterized by where G is galactose, N is N-acetylglucosamine and M is mannose.
本発明にかかる抗炎症性非フコシル化免疫グロブリン製剤の製造方法は、ヒト血清IgG抗体にエンドグリコシダーゼ S (Endo S)を用いて、Fc部分のアスパラギン297(Asn297)残基に結合している糖鎖をキトビオースコアで切断し、Asn297残基に結合しているN-アセチルグルコサミン及び該N-アセチルグルコサミンに結合したフコース以外を除去する糖鎖除去工程と、α-L-フコシダーゼ (AlfC)を用いて前記N-アセチルグルコサミンに結合したフコースを除去するフコース除去工程と、グリコシンターゼ (Endo S D233Q)を用いて、ガラクトシルグリコペプチドから調製したオキサゾリン化糖鎖(GG-Ox)を、ヒト血清IgG抗体のFc部分のアスパラギン297(Asn297)残基に結合しているN-アセチルグルコサミンに転移する転移工程と、を有することを特徴とする。 The method for producing an anti-inflammatory non-fucosylated immunoglobulin preparation according to the present invention uses endoglycosidase S (Endo S) on a human serum IgG antibody to extract a sugar bound to the asparagine 297 (Asn297) residue of the Fc portion. A sugar chain removal step of cleaving the chain with the chitobiose core, removing N-acetylglucosamine bound to the Asn297 residue and other than fucose bound to the N-acetylglucosamine, and using α-L-fucosidase (AlfC) The fucose-removing step of removing fucose bound to N-acetylglucosamine and glycosynthase (Endo S D233Q) were used to quantify oxazoline sugar chains (GG-Ox) prepared from galactosyl glycopeptides as human serum IgG antibodies. and a transfer step of transferring to N-acetylglucosamine bound to the asparagine 297 (Asn297) residue of the Fc portion.
本発明によれば、自己免疫疾患等の炎症性疾患に対する新しい治療薬が得られる。 INDUSTRIAL APPLICABILITY According to the present invention, new therapeutic agents for inflammatory diseases such as autoimmune diseases are obtained.
以下、添付の図面を参照して本発明の実施形態について具体的に説明するが、当該実施形態は本発明の原理の理解を容易にするためのものであり、本発明の範囲は、下記の実施形態に限られるものではなく、当業者が以下の実施形態の構成を適宜置換した他の実施形態も、本発明の範囲に含まれる。 Hereinafter, embodiments of the present invention will be specifically described with reference to the accompanying drawings. The embodiments are intended to facilitate understanding of the principles of the present invention, and the scope of the present invention is as follows. The scope of the present invention is not limited to the embodiments, and other embodiments in which the configurations of the following embodiments are appropriately replaced by those skilled in the art are also included in the scope of the present invention.
本実施形態にかかる抗炎症性非フコシル化免疫グロブリン製剤は、包含されるIgG抗体が、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体からなることを特徴とする。ここでSはシアル酸、Gはガラクトース、NはN-アセチルグルコサミン、Mはマンノースである。 In the anti-inflammatory non-fucosylated immunoglobulin preparation according to this embodiment, the IgG antibody to be included consists of a human serum IgG antibody in which the sugar chain shown below is bound to asparagine 297 (Asn297) of the Fc portion. characterized by where S is sialic acid, G is galactose, N is N-acetylglucosamine and M is mannose.
また、本実施形態にかかる抗炎症性非フコシル化免疫グロブリン製剤は、包含されるIgG抗体が、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体からなることを特徴とする。ここでGはガラクトース、NはN-アセチルグルコサミン、Mはマンノースである。 In addition, the anti-inflammatory non-fucosylated immunoglobulin preparation according to this embodiment contains human serum IgG antibodies in which the sugar chain shown below is bound to asparagine 297 (Asn297) of the Fc portion. characterized by becoming where G is galactose, N is N-acetylglucosamine and M is mannose.
免疫グロブリンは、抗体および抗体フラグメント(scFv、Fab、Fc、F(ab’)2)ならびに抗体の他の遺伝子工学的に処理した部分を含むが、これらに限定されない。免疫グロブリンすなわち抗体は、すべての哺乳動物の血清や組織体液中に存在する糖タンパク質の一群である。IgG(Immunoglobulin G)は、正常ヒト血清中の免疫グロブリンの約75～85%を占める。糖鎖はIgG全体の立体構造を保つ上でも重要な働きをもっており、その糖鎖は中性化糖鎖として16種類存在している。IgGの糖鎖構造は、非常に不均一な糖鎖の混合物により構成されているが、健常人ではその16種類の相対比率は、ほぼ一定である。なお骨髄腫患者やリューマチ患者の糖鎖は、非常に特異な相対比率を示すことが知られている。 Immunoglobulins include, but are not limited to, antibodies and antibody fragments (scFv, Fab, Fc, F(ab')2) and other engineered portions of antibodies. Immunoglobulins, or antibodies, are a group of glycoproteins present in the serum and tissue fluids of all mammals. IgG (Immunoglobulin G) accounts for about 75-85% of the immunoglobulins in normal human serum. Sugar chains also play an important role in maintaining the three-dimensional structure of IgG as a whole, and there are 16 types of these sugar chains as neutralized sugar chains. The sugar chain structure of IgG is composed of a highly heterogeneous mixture of sugar chains, but the relative proportions of the 16 types are almost constant in healthy subjects. It is known that sugar chains in myeloma and rheumatoid arthritis patients exhibit a very specific relative ratio.
抗体依存性細胞傷害活性(ADCC)は、標的細胞に結合した抗体がナチュラルキラー細胞(NK細胞)やマクロファージなどのエフェクター細胞上のFc受容体と結合することで、抗体依存的に誘導される標的細胞傷害活性である。抗体医薬の薬効発現に、ADCC活性は最も重要なものの１つと考えられている。 Antibody-dependent cellular cytotoxicity (ADCC) is a target that is induced in an antibody-dependent manner by binding antibodies bound to target cells to Fc receptors on effector cells such as natural killer cells (NK cells) and macrophages. Cytotoxic activity. ADCC activity is considered to be one of the most important factors in the efficacy of antibody drugs.
1分子のIgG型抗体のFc領域に２つのN-グリコシド結合糖鎖が結合している。この抗体のN-グリコシド結合糖鎖は、マンノシル-キトビオースコア (Mannosyl-chitobiose Core)構造を基本構造とする複合型2本鎖糖鎖であり、非還元末端側ではガラクトース及びシアル酸の有無について、還元末端ではフコースの有無について多様性が存在している。 Two N-glycoside-linked sugar chains are bound to the Fc region of one molecule of IgG antibody. The N-glycoside-linked sugar chain of this antibody is a complex-type two-chain sugar chain with a mannosyl-chitobiose core structure as the basic structure. Diversity exists in the presence or absence of fucose at the terminal end.
抗体Fc領域に結合するN-グリコシド結合複合型糖鎖還元末端のN-アセチルグルコサミンからフコース残基を除去すると、Fcγ受容体IIIaに対する親和性が上がる。本明細書において、シアル酸を末端に有する非フコシル化IgGをIgG(S2)と表記することができ(単に非フコシル化IgGと称することも可能である。)、ガラクトースを末端に有する非フコシル化IgGをIgG(G2)と表記することができる(ガラクトシル非フコシル化IgGと称することも可能である。)。 Removal of the fucose residue from N-acetylglucosamine at the reducing end of the N-glycoside-linked complex-type sugar chain that binds to the antibody Fc region increases the affinity for Fcγ receptor IIIa. In this specification, the non-fucosylated IgG having sialic acid at the terminal can be denoted as IgG (S2) (it can also be simply referred to as non-fucosylated IgG), and the non-fucosylated IgG having galactose at the terminal IgG can be designated as IgG(G2) (it can also be referred to as non-galactosyl fucosylated IgG).
IgG(S2)は、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合している構造を有する。ここでSはシアル酸、Gはガラクトース、NはN-アセチルグルコサミン、Mはマンノースである。 IgG(S2) has a structure in which the sugar chain shown below is bound to asparagine 297 (Asn297) in the Fc portion. where S is sialic acid, G is galactose, N is N-acetylglucosamine and M is mannose.
IgG(G2)は、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合している構造を有する。ここでGはガラクトース、NはN-アセチルグルコサミン、Mはマンノースである。 IgG(G2) has a structure in which the sugar chain shown below is bound to asparagine 297 (Asn297) in the Fc portion. where G is galactose, N is N-acetylglucosamine and M is mannose.
なお、包含されるIgG抗体が、所定糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体からなるとは、所定糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体が免疫グロブリン製剤中に包含されるIgG抗体中に95％～100％包含される、好ましくは98％～100％包含される、最も好ましくは100%包含されることである。 The IgG antibody to be included is composed of a human serum IgG antibody in which a predetermined sugar chain is bound to asparagine 297 (Asn297) of the Fc portion means that the predetermined sugar chain is bound to asparagine 297 (Asn297) of the Fc portion. The present human serum IgG antibody is 95% to 100% contained in the IgG antibody contained in the immunoglobulin preparation, preferably 98% to 100% contained, most preferably 100% contained.
そのため、包含されるIgG抗体が、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体からなる、抗炎症性非フコシル化免疫グロブリン製剤(ここでSはシアル酸、Gはガラクトース、NはN-アセチルグルコサミン、Mはマンノースである。)とは、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体が免疫グロブリン製剤中に包含されるIgG抗体中に95％～100％包含される、好ましくは98％～100％包含される、最も好ましくは100%包含されることである。 Therefore, an anti-inflammatory non-fucosylated immunoglobulin preparation (where S is sialic acid, G is galactose, N is N-acetylglucosamine, and M is mannose.) is immunized by a human serum IgG antibody in which the sugar chain shown below is bound to asparagine 297 (Asn297) in the Fc portion. It should be 95% to 100%, preferably 98% to 100%, most preferably 100%, in the IgG antibody included in the globulin preparation.
また、包含されるIgG抗体が、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体からなる、抗炎症性非フコシル化免疫グロブリン製剤(ここでGはガラクトース、NはN-アセチルグルコサミン、Mはマンノースである。)とは、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgG抗体が免疫グロブリン製剤中に包含されるIgG抗体中に95％～100％包含される、好ましくは98％～100％包含される、最も好ましくは100%包含されることである。 Also included is an anti-inflammatory non-fucosylated immunoglobulin preparation (where G is Galactose, N is N-acetylglucosamine, and M is mannose.) is a human serum IgG antibody in which the sugar chain shown below is bound to asparagine 297 (Asn297) of the Fc portion is included in immunoglobulin preparations. 95% to 100% coverage, preferably 98% to 100% coverage, most preferably 100% coverage in the IgG antibody used.
一方でフコシル化IgGをIgG(S2F)と表記することができ、IgG(S2F)は、下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合している構造を有する。ここでSはシアル酸、Gはガラクトース、NはN-アセチルグルコサミン、Mはマンノース、Fはフコースである。 On the other hand, fucosylated IgG can be denoted as IgG(S2F), and IgG(S2F) has a structure in which the sugar chain shown below is bound to asparagine 297 (Asn297) of the Fc portion. Here S is sialic acid, G is galactose, N is N-acetylglucosamine, M is mannose and F is fucose.
図2に示されるように、フコシル化IgGは、自己抗体-抗原複合体とNK細胞上のFcγ受容体IIIaとの相互作用を阻害できないが、一方で、非フコシル化IgG(図2のBで示される非フコシル化血清IgGは、IgG(S2)又はIgG(G2)である。)は、NK細胞上のFcγ受容体IIIaに強く結合してNK細胞の殺作用を阻害し、その結果として炎症が抑制されると考えられる。 As shown in Figure 2, fucosylated IgG cannot inhibit the interaction of autoantibody-antigen complexes with Fcγ receptor IIIa on NK cells, whereas non-fucosylated IgG (Figure 2B The non-fucosylated serum IgG shown is IgG(S2) or IgG(G2).) strongly binds to the Fcγ receptor IIIa on NK cells and inhibits killing of NK cells, resulting in inflammation. is thought to be suppressed.
本発明の免疫グロブリン製剤は、液状製剤の場合は、そのままで、あるいは適当な溶媒(例えば、注射用蒸留水、生理食塩水、ブドウ糖液等)で希釈して使用され、乾燥製剤の場合は、上記免疫グロブリン溶液を凍結乾燥をした後、使用時に適当な溶媒(例えば、注射用蒸留水等)に溶解して使用される。 When the immunoglobulin preparation of the present invention is a liquid preparation, it is used as it is or after being diluted with an appropriate solvent (e.g., distilled water for injection, physiological saline, glucose solution, etc.). After freeze-drying the immunoglobulin solution, it is dissolved in an appropriate solvent (eg, distilled water for injection, etc.) before use.
本発明の免疫グロブリン製剤の投与経路は、通常注射であり、特に静脈内投与が好ましい。本発明の免疫グロブリン製剤の投与量は、体重１ｋｇ当たり免疫グロブリンとして50～1000mg／日を、１～数日間連日静脈内投与することが標準的であるが、症状、性別、体重等に応じて投与量を増減すればよい。 The administration route of the immunoglobulin formulation of the present invention is usually injection, and intravenous administration is particularly preferred. The dosage of the immunoglobulin preparation of the present invention is typically 50 to 1000 mg/day of immunoglobulin per 1 kg of body weight by intravenous administration for one to several days, depending on symptoms, sex, body weight, etc. The dosage may be increased or decreased.
本発明にかかる免疫グロブリン溶液は、本発明の目的に反しない範囲で、通常医薬品に用いられる薬理的に許容される添加剤(例えば、担体、賦形剤、希釈剤等)、安定化剤または製薬上必要な成分を含有してもよい。 The immunoglobulin solution according to the present invention contains pharmacologically acceptable additives (e.g., carriers, excipients, diluents, etc.), stabilizers, or Pharmaceutically necessary ingredients may be contained.
安定化剤としては、グルコース等の単糖類、サッカロース、マルトース等の二糖類、マンニトール、ソルビトール等の糖アルコール、塩化ナトリウム等の中性塩、グリシン等のアミノ酸、ポリエチレングリコール、ポリオキシエチレン-ポリオキシプロピレン共重合体(プルロニック（登録商標）)、ポリオキシエチレンソルビタン脂肪酸エステル(トゥイーン)等の非イオン系界面活性剤等が例示され、1～10w/v%程度添加されていることが好ましい。 Stabilizers include monosaccharides such as glucose, disaccharides such as saccharose and maltose, sugar alcohols such as mannitol and sorbitol, neutral salts such as sodium chloride, amino acids such as glycine, polyethylene glycol, polyoxyethylene-polyoxy Examples include nonionic surfactants such as propylene copolymer (Pluronic (registered trademark)) and polyoxyethylene sorbitan fatty acid ester (Tween), which are preferably added in an amount of about 1 to 10 w/v%.
本発明にかかる免疫グロブリン製剤の投与対象となる疾患は、特に限定されるものではないが、例えば、川崎病、特発性血小板減少性紫斑病、ギラン・バレー症候群、多発性硬化症、慢性関節リウマチ、全身性エリテマトーデス、天疱瘡、類天疱瘡、重症筋無力症、ANCA関連血管炎、慢性炎症性脱髄性多発神経炎、自己免疫性好中球減少症、自己免疫性溶血性貧血、自己免疫性後天性凝固第VIII因子欠乏症、スティフ・パーソン症候群、多病巣性神経障害、ベーチェット病、潰瘍性大腸炎、クローン病、Reiter関節炎、多発性筋炎、皮膚筋炎、限局性強皮症、全身性強皮症、Sjogren症候群、抗糸球体基底膜腎炎、原発性硬化性胆管炎、原発性抗リン脂質抗体症候群、中毒性表皮壊死症、移植片対宿主病、敗血症 などが挙げられる。 Diseases to which the immunoglobulin preparation of the present invention is administered are not particularly limited, but examples include Kawasaki disease, idiopathic thrombocytopenic purpura, Guillain-Barre syndrome, multiple sclerosis, and rheumatoid arthritis. , systemic lupus erythematosus, pemphigus, pemphigoid, myasthenia gravis, ANCA-associated vasculitis, chronic inflammatory demyelinating polyneuropathy, autoimmune neutropenia, autoimmune hemolytic anemia, autoimmunity Acquired coagulation factor VIII deficiency, stiff-person syndrome, multifocal neuropathy, Behcet's disease, ulcerative colitis, Crohn's disease, Reiter's arthritis, polymyositis, dermatomyositis, localized scleroderma, generalized hyperthermia Dermatitis, Sjogren's syndrome, anti-glomerular basement nephritis, primary sclerosing cholangitis, primary antiphospholipid antibody syndrome, toxic epidermal necrolysis, graft-versus-host disease, sepsis, etc.
なおモノクローナルIgG抗体のFc部位の糖鎖からフコースを除去した抗体医薬が抗体依存性細胞傷害(ADCC)を増強する目的で開発されてきた(例Mogamulizumab(商品名 PoteligeoTM))。従来の非フコシル化抗体は、糖鎖関連遺伝子を操作した哺乳類宿主細胞から産生された抗原特異的なモノクローナル抗体であり、適応対象は悪性腫瘍である。一方、本願発明にかかる免疫グロブリンは血清由来の非特異IgG抗体のフコースを酵素的に除去した後に均一な糖鎖を化学酵素反応により転移したものであり、適応対象は自己免疫疾患である。即ち、本願発明にかかる免疫グロブリン製剤は自己抗体による望ましくない免疫応答を阻害する目的で使用される。 An antibody drug obtained by removing fucose from the sugar chain of the Fc portion of a monoclonal IgG antibody has been developed for the purpose of enhancing antibody-dependent cellular cytotoxicity (ADCC) (eg, Mogamulizumab (trade name PoteligeoTM)). Conventional non-fucosylated antibodies are antigen-specific monoclonal antibodies produced from mammalian host cells in which carbohydrate-related genes have been engineered, and are indicated for malignant tumors. On the other hand, the immunoglobulin according to the present invention is obtained by enzymatically removing fucose from serum-derived non-specific IgG antibodies and then transferring uniform sugar chains by chemical enzymatic reaction, and is applicable to autoimmune diseases. That is, the immunoglobulin preparation according to the present invention is used for the purpose of inhibiting unwanted immune responses caused by autoantibodies.
本実施形態にかかる抗炎症性非フコシル化免疫グロブリン製剤の製造方法は、ヒト血清IgG抗体のFc部分のアスパラギン297(Asn297)残基に結合している糖鎖をキトビオースコアで切断し、Asn297残基に結合しているN-アセチルグルコサミン及び該N-アセチルグルコサミンに結合したフコース以外を除去する糖鎖除去工程と、前記N-アセチルグルコサミンに結合したフコースを除去するフコース除去工程と、グリコシンターゼ(Endo S D233Q)を用いて、卵黄由来シアリルグリコペプチドから調製したオキサゾリン化糖鎖(SG-Ox)を、ヒト血清IgG抗体のFc部分のアスパラギン297(Asn297)残基に結合しているN-アセチルグルコサミンに転移させる転移工程と、を有する。 In the method for producing an anti-inflammatory non-fucosylated immunoglobulin preparation according to this embodiment, the sugar chain bound to the asparagine 297 (Asn297) residue of the Fc portion of the human serum IgG antibody is cleaved with a chitobiose core, and the Asn297 residue is A sugar chain removal step of removing other than N-acetylglucosamine bound to and fucose bound to the N-acetylglucosamine, a fucose removal step of removing fucose bound to the N-acetylglucosamine, a glycosynthase (Endo N-acetylglucosamine conjugated to the asparagine 297 (Asn297) residue of the Fc portion of the human serum IgG antibody by using S D233Q) to oxazoline sugar chains (SG-Ox) prepared from egg yolk-derived sialylglycopeptides. and a transition step of transitioning to.
本実施形態にかかる抗炎症性非フコシル化免疫グロブリン製剤の製造方法は、ヒト血清IgG抗体にエンドグリコシダーゼ S (Endo S)を用いて、Fc部分のアスパラギン297(Asn297)残基に結合している糖鎖をキトビオースコアで切断し、Asn297残基に結合しているN-アセチルグルコサミン及び該N-アセチルグルコサミンに結合したフコース以外を除去する糖鎖除去工程と、α-L-フコシダーゼ (AlfC)を用いて前記N-アセチルグルコサミンに結合したフコースを除去するフコース除去工程と、グリコシンターゼ (Endo S D233Q)を用いて、卵黄由来ガラクトシルグリコペプチドから調製したオキサゾリン化糖鎖(GG-Ox)を、ヒト血清IgG抗体のFc部分のアスパラギン297(Asn297)残基に結合しているN-アセチルグルコサミンに転移する転移工程と、を有することを特徴とする抗炎症性非フコシル化免疫グロブリン製剤の製造方法。 In the method for producing an anti-inflammatory non-fucosylated immunoglobulin preparation according to this embodiment, human serum IgG antibody is bound to asparagine 297 (Asn297) residue of the Fc portion using endoglycosidase S (Endo S). A sugar chain removal step of cleaving the sugar chain with the chitobiose core, removing N-acetylglucosamine bound to the Asn297 residue and other than fucose bound to the N-acetylglucosamine, and α-L-fucosidase (AlfC) and glycosynthase (Endo S D233Q) to remove fucose bound to the N-acetylglucosamine. and a transfer step of transferring to N-acetylglucosamine bound to the asparagine 297 (Asn297) residue of the Fc portion of an IgG antibody.
Fc部分のアスパラギン297(Asn297)残基に結合している糖鎖をキトビオースコアで切断する酵素は、エンドグリコシダーゼ S (Endo S)である。 Endoglycosidase S (Endo S) is an enzyme that cleaves the sugar chain bound to the asparagine 297 (Asn297) residue of the Fc portion with the chitobiose core.
N-アセチルグルコサミンに結合したフコースを除去する酵素は、α-L-フコシダーゼ (AlfC)である。α-L-フコシダーゼには、1,2-α-L-フコシダーゼ、1,3-α-L-フコシダーゼ、又は、1,6-α-L-フコシダーゼがあるが、ここでは1,6-α-L-フコシダーゼを用いることが好ましい。 The enzyme that removes fucose bound to N-acetylglucosamine is α-L-fucosidase (AlfC). α-L-fucosidase includes 1,2-α-L-fucosidase, 1,3-α-L-fucosidase, or 1,6-α-L-fucosidase, where 1,6-α -L-fucosidase is preferably used.
オキサゾリン化糖鎖(SG-Ox又はGG-Ox)はシアリルグリカンの還元末端を脱水縮合して調製される。 Oxazolylated sugar chains (SG-Ox or GG-Ox) are prepared by dehydration condensation of the reducing end of sialylglycan.
SG-Ox又はGG-Oxを糖鎖除去したIgGへ転移する酵素は、グリコシンターゼ (Endo S D233Q)である。 The enzyme that transfers SG-Ox or GG-Ox to deglycosylated IgG is glycosynthase (Endo S D233Q).
1.抗炎症性非フコシル化免疫グロブリン製剤の製造
1a-1.血清由来IgGの精製
健常人血液から調製した血清20 mlを0.01M リン酸緩衝液(pH 7.0)で透析後、同じ緩衝液で平衡化したDiethylaminoethyl (DEAE)-cellulose 陰イオン交換カラム(DE52, Whatman Biosystems, Chalfont, St Giles, UK)(1 x 30 cm)に添加し、素通りした分画に含まれるIgGを採取した。血清IgGの糖鎖構造は、後述の通りHigh performance liquid chromatographyで分析し(図5-A)、95 %以上がフコシル化であることを確認した。
1. Manufacture of anti-inflammatory non-fucosylated immunoglobulin formulation
1a-1. Purification of serum-derived
1a-2.血清IgGの脱グリコシル化
IgGのFc結合糖鎖を切断するエンドグリコシダーゼとして、Endo Sを用いた。糖鎖のキトビオースコアの２つのN-アセチルグルコサミン間を加水分解し、N-アセチルグルコサミンとフコースの二糖を残し、脱グリコシル化した。脱グリコシル化IgG は、Protein G-Sepharose 4(GE)で精製した。
1a-2. Deglycosylation of serum IgG
Endo S was used as an endoglycosidase that cleaves the Fc-linked sugar chain of IgG. It was hydrolyzed between two N-acetylglucosamines in the chitobiose core of the sugar chain, leaving the disaccharide of N-acetylglucosamine and fucose and deglycosylated. Deglycosylated IgG was purified on Protein G-Sepharose 4 (GE).
1a-3.血清IgGの脱フコシル化
フコースの除去にα-L-フコシダーゼ(AlfC)を用いた。本酵素の発現ベクターのDNA配列は以前報告され(配列番号1)、BL21(DE3)大腸菌で文献に準じて発現させる。Endo Sで脱グリコシル化したIgG にAlfC を50 mM Tris-HCl (pH 7.4)中で37℃一晩反応させ、フコースを除去した。
1a-3. Defucosylation of serum IgG α-L-fucosidase (AlfC) was used to remove fucose. The DNA sequence of the expression vector for this enzyme was previously reported (SEQ ID NO: 1) and is expressed in BL21(DE3) E. coli according to the literature. Endo S deglycosylated IgG was reacted with AlfC in 50 mM Tris-HCl (pH 7.4) overnight at 37°C to remove fucose.
1a-4.シアリルグリカンオキサゾリン(SG-Ox)の生成
下記に示すシアリルグリコペプチド(10 mg, 東京化成)を50 mM リン酸緩衝液(pH 6.0)中にてEndo Sで糖鎖を切断し、2-Chloro-1,3-dimethylimidazolinium Chloride(東京化成)とtriethylamineを加え、0℃で１時間放置し、還元末端の脱水縮合反応によりSG-Ox を調製した。
1a-4. Production of sialylglycan oxazoline (SG-Ox) The sugar chain of the sialylglycopeptide (10 mg, Tokyo Kasei) shown below was cleaved with Endo S in 50 mM phosphate buffer (pH 6.0), 2-Chloro-1,3-dimethylimidazolinium Chloride (Tokyo Kasei Co., Ltd.) and triethylamine were added, left at 0°C for 1 hour, and SG-Ox was prepared by dehydration condensation reaction of the reducing end.
図4はEndo Sで遊離したシアリル糖鎖からのオキサゾリン化糖鎖(SG-Ox)の生成工程を示す。下記にSG-Oxの構造を示す。 FIG. 4 shows the production process of oxazoline sugar chains (SG-Ox) from sialyl sugar chains released by Endo S. The structure of SG-Ox is shown below.
1a-5.非フコシル化IgGの作製
グリコシンターゼEndo S D233Qの発現ベクターのDNA配列は文献に報告され(配列番号2)、BL21(DE3)大腸菌で発現させる。糖鎖転移反応はSG-Oxを用いて、50 mM Tris-HCl (pH 7.4)、37℃で3時間インキュベートして行った。これにより本実施例にかかる抗炎症性非フコシル化免疫グロブリン製剤を製造した。この本実施例にかかる非フコシル化IgGをIgG(S2)と表記することができる。IgG(S2)およびそのフコシル化したIgGであるIgG(S2F)はともに純度がSDS-PAGEで95％以上であることを確認した(図3)。下記にSG-OxのGlcNAc-IgGへの糖鎖転移反応を示す。
1a-5. Production of non-fucosylated IgG The DNA sequence of the expression vector for the glycosynthase Endo S D233Q was reported in the literature (SEQ ID NO: 2) and is expressed in BL21(DE3) E. coli. Glycosylation reaction was performed using SG-Ox by incubating at 37° C. for 3 hours in 50 mM Tris-HCl (pH 7.4). This produced an anti-inflammatory non-fucosylated immunoglobulin preparation according to this example. This non-fucosylated IgG according to this example can be denoted as IgG(S2). Both IgG(S2) and its fucosylated IgG, IgG(S2F), were confirmed to have a purity of 95% or more by SDS-PAGE (Fig. 3). The transglycosylation reaction of SG-Ox to GlcNAc-IgG is shown below.
本実施例にかかる抗炎症性非フコシル化免疫グロブリン製剤において、糖鎖の改変を確認するために、糖鎖をすげ替えたIgG(S2)及びIgG(S2F)をN-グリコシダーゼF 消化し糖鎖を遊離した後、2-aminobenzamide で蛍光標識し、High performance liquid chromatography (HPLC)で分析した。なおIgG(S2F)は比較例にかかるフコシル化IgGであり具体的には下記で示される糖鎖がFc部分のアスパラギン297(Asn297)に結合しているヒト血清IgGである。 In the anti-inflammatory non-fucosylated immunoglobulin preparation according to this example, in order to confirm the modification of the sugar chain, IgG(S2) and IgG(S2F) in which the sugar chain was replaced were digested with N-glycosidase F to remove the sugar chain. After release, they were fluorescently labeled with 2-aminobenzamide and analyzed by high performance liquid chromatography (HPLC). IgG(S2F) is a fucosylated IgG according to a comparative example, specifically human serum IgG in which the sugar chain shown below is bound to asparagine 297 (Asn297) in the Fc portion.
図5に示されるように、対照IgGの糖鎖はほぼフコースを有するが、本実施例にかかる抗炎症性非フコシル化免疫グロブリン製剤のIgG(S2)ではフコースが除去されていることが確認できた。 As shown in FIG. 5, the sugar chains of the control IgG mostly contain fucose, whereas the anti-inflammatory non-fucosylated immunoglobulin preparation IgG(S2) according to the present example has fucose removed. rice field.
1b.非フコシル化血清IgGによるADCC 抑制(抗炎症)効果
本実施例にかかる抗炎症性非フコシル化免疫グロブリン製剤の抗炎症作用を以下の手法にて確認した。
1b. ADCC Suppressive (Anti-Inflammatory) Effect by Non-Fucosylated Serum IgG The anti-inflammatory action of the anti-inflammatory non-fucosylated immunoglobulin preparation according to this example was confirmed by the following method.
予備実験として、通常の血清IgG(95％フコシル化IgGであり、図5のAに示される対照IgGである)が、ADCCに及ぼす影響をADCC Reporter bioassay kit(プロメガ社)により調べた。標的細胞をハプテン(4-hydroxy-3-iodo-5-nitrophenacetyl)で標識し、抗ハプテンモノクローナルIgG 抗体で感作した(0.001～3 μg/ml)(図6)。 As a preliminary experiment, the effect of normal serum IgG (95% fucosylated IgG, control IgG shown in FIG. 5A) on ADCC was examined using the ADCC Reporter bioassay kit (Promega). Target cells were labeled with a hapten (4-hydroxy-3-iodo-5-nitrophenacetyl) and sensitized with an anti-hapten monoclonal IgG antibody (0.001-3 µg/ml) (Figure 6).
抗ハプテンIgG のADCC活性の強弱は、標的細胞死(Cytotoxicity、図6, Y軸)を最大レベルの50％を誘導できる抗ハプテンIgG 濃度(EC50)で示される。EC50が低いほど、特異抗体のADCC活性は高いと解釈できる。血清IgG を0.01, 0.1, 1, 8 mg/ml の濃度でADCC測定系に加えて、抗ハプテンIgGのEC50を比較したところ、加えた血清IgG の濃度が高いほどEC50が上昇(X 軸右側へシフト)し、ADCCが抑制されることが示された(図6)。 The strength of the ADCC activity of anti-hapten IgG is indicated by the anti-hapten IgG concentration (EC50) capable of inducing 50% of the maximal level of target cell death (Cytotoxicity, Figure 6, Y-axis). It can be interpreted that the lower the EC50, the higher the ADCC activity of the specific antibody. Serum IgG was added to the ADCC measurement system at concentrations of 0.01, 0.1, 1, and 8 mg/ml, and the EC50 of anti-hapten IgG was compared. shift), indicating that ADCC was suppressed (Fig. 6).
一方、糖鎖改変した血清IgGである非フコシル化IgG(S2)とフコシル化IgG(S2F)の間で、ADCC抑制作用に差があるか調べるために、それらの存在下で抗CD20 IgG のADCC 活性を比較した(図7)。S2及びS2F濃度は0.1 mg/ml とした。S2Fでは対照と同じEC50(0.2μg/ml)となり、抑制作用を示さなかった(図7)。一方、S2存在下では、EC50 は15倍以上高濃度の>3μg/mlとなった(図7)。つまり、S2はS2Fの15倍以上のADCC 抑制作用を発揮したといえる。従って、非フコシル化IVIG を用いれば、通常のIVIGよりも少量の投与量で抗炎症効果が期待でき、更に通常のIVIGが有効でない症例に対しても抗炎症効果を発揮する可能性がある。 On the other hand, in order to investigate whether there is a difference in ADCC inhibitory action between non-fucosylated IgG (S2) and fucosylated IgG (S2F), which are glycosylated serum IgG, ADCC of anti-CD20 IgG was tested in the presence of them. Activities were compared (Fig. 7). The S2 and S2F concentrations were 0.1 mg/ml. S2F showed the same EC50 (0.2 μg/ml) as the control, showing no inhibitory action (Fig. 7). On the other hand, in the presence of S2, the EC50 was >3 μg/ml, a more than 15-fold higher concentration (Fig. 7). In other words, it can be said that S2 exerted an ADCC inhibitory effect 15 times or more that of S2F. Therefore, if non-fucosylated IVIG is used, anti-inflammatory effects can be expected with a smaller dosage than conventional IVIG, and there is a possibility that anti-inflammatory effects can be exhibited even in cases where conventional IVIG is not effective.
2.抗炎症性ガラクトシル非フコシル化免疫グロブリン製剤の製造
2a-1.血清由来IgGの精製
健常人血液から調製した血清20 mlを0.01M リン酸緩衝液(pH 7.0)で透析後、同じ緩衝液で平衡化したDiethylaminoethyl (DEAE)-cellulose 陰イオン交換カラム(DE52, Whatman Biosystems, Chalfont, St Giles, UK)(1 x 30 cm)に添加し、素通りした分画に含まれるIgGを採取した。純度はSDS-PAGEで95％以上であることを確認した(図8、レーン1)。
2. Manufacture of anti-inflammatory galactosyl non-fucosylated immunoglobulin preparation
2a-1. Purification of serum-derived
2a-2.血清IgGの糖鎖切断
IgGのFc結合糖鎖を切断するエンドグリコシダーゼとして、Endo Sを用いた。Endo S の発現ベクターのDNA 配列は以前報告され、BL21(DE3)大腸菌で発現させた。臭化シアン活性化Sepharose 4B ビーズに固定化したEndo Sを用いて、糖鎖のキトビオースコアの２つのN-アセチルグルコサミン間を加水分解し、N-アセチルグルコサミンとフコースの二糖を残し、脱グリコシル化した。脱グリコシル化IgG は、Protein G-Sepharose 4(GE)で精製した。
2a-2. Glycolysis of serum IgG
Endo S was used as an endoglycosidase that cleaves the Fc-linked sugar chain of IgG. The DNA sequence of the Endo S expression vector was previously reported and expressed in BL21(DE3) E. coli. Using Endo S immobilized on cyanogen bromide-activated Sepharose 4B beads, hydrolysis between the two N-acetylglucosamines of the chitobiose core of the glycan leaves a disaccharide of N-acetylglucosamine and fucose, followed by deglycosylation. did. Deglycosylated IgG was purified on Protein G-Sepharose 4 (GE).
2a-3.血清IgGの脱フコシル化
フコースの除去にα-L-フコシダーゼ(AlfC)を用いた。本酵素の発現ベクターのDNA配列は以前報告され(配列番号1)、BL21(DE3)大腸菌で文献に準じて発現させる。Endo Sで脱グリコシル化したIgG にAlfC を50 mM Tris-HCl (pH 7.4)中で37℃一晩反応させ、フコースを除去した。
2a-3. Defucosylation of serum IgG α-L-fucosidase (AlfC) was used to remove fucose. The DNA sequence of the expression vector for this enzyme was previously reported (SEQ ID NO: 1) and is expressed in BL21(DE3) E. coli according to the literature. Endo S deglycosylated IgG was reacted with AlfC in 50 mM Tris-HCl (pH 7.4) overnight at 37°C to remove fucose.
2a-4.ガラクトシルグリカンオキサゾリン(GG-Ox)の生成
シアリルグリコペプチド(10mg, 東京化成)を50mM リン酸緩衝液 (pH 6.0) 中にてシアリダーゼ (Roche) およびSepharose固定化Endo Sと一晩37℃で反応させる。下記に示すガラクトシルグリコペプチドが中間体となり、その糖鎖が切断され、ガラクトシルグリカンが生成する。更に2-Chloro-1,3-dimethylimidazolinium Chloride(東京化成)とtriethylamineを加え、0℃で１時間放置し、還元末端の脱水縮合反応によりGG-Ox を調製した。GG-Ox はセルロースカラム(Sigma-Aldrich)で精製した。
2a-4. Generation of galactosylglycan oxazoline (GG-Ox) A sialyl glycopeptide (10 mg, Tokyo Kasei) was treated with sialidase (Roche) and Sepharose-immobilized Endo S in 50 mM phosphate buffer (pH 6.0) overnight. °C. A galactosyl glycopeptide shown below serves as an intermediate, and its sugar chain is cleaved to produce a galactosyl glycan. Furthermore, 2-Chloro-1,3-dimethylimidazolinium Chloride (Tokyo Kasei) and triethylamine were added, left at 0°C for 1 hour, and GG-Ox was prepared by dehydration condensation reaction of the reducing end. GG-Ox was purified on a cellulose column (Sigma-Aldrich).
図9はEndo Sで遊離した糖鎖からのGG-Oxの生成工程を示す。下記にGG-Oxの構造を示す。 FIG. 9 shows the production process of GG-Ox from sugar chains released by Endo S. The structure of GG-Ox is shown below.
2a-5.ガラクトシル非フコシル化IgGの作製
グリコシンターゼEndo S D233Qの発現ベクターのDNA配列は文献に報告され、BL21(DE3)大腸菌で発現させる。糖鎖転移反応では、GG-Oxを用いて、Endo S D233Qと50 mM Tris-HCl (pH 7.4)、30℃で4時間インキュベートして行った。これにより本実施例にかかる抗炎症性ガラクトシル非フコシル化免疫グロブリン製剤を製造した。この本実施例にかかるガラクトシル非フコシル化IgGをIgG(G2)と表記することができる。糖鎖の改変を確認するために、糖鎖をすげ替えたIgG(S2、S2F、G2)をN-グリコシダーゼF消化し糖鎖を遊離した後、2-aminobenzamideで蛍光標識し、High performance liquid chromatography (HPLC)で分析した(図10)。下記にGG-OxのGlcNAc-IgGへの糖鎖転移反応を示す。
2a-5. Generation of non-galactosylfucosylated IgG The DNA sequence of the expression vector for the glycosynthase Endo S D233Q is reported in the literature and is expressed in BL21(DE3) E. coli. In the transglycosylation reaction, Endo S D233Q and 50 mM Tris-HCl (pH 7.4) were incubated at 30°C for 4 hours using GG-Ox. This produced an anti-inflammatory galactosyl non-fucosylated immunoglobulin formulation according to this example. This non-galactosyl-fucosylated IgG according to this example can be denoted as IgG(G2). In order to confirm the modification of the sugar chain, IgG (S2, S2F, G2) with the substituted sugar chain was digested with N-glycosidase F to release the sugar chain, followed by fluorescent labeling with 2-aminobenzamide and high performance liquid chromatography ( HPLC) (Fig. 10). The transglycosylation reaction of GG-Ox to GlcNAc-IgG is shown below.
2b. ガラクトシル非フコシル化免疫グロブリンのADCC抑制(抗炎症)効果
フコースを除去した血清IgG が抗炎症作用を持ち、更にガラクトースを末端に持つ事で、その作用が増強される事を以下の方法で発見した。予備実験として、通常の血清IgG(IVIG、95％フコシル化、図10A)の存在がADCCに及ぼす影響をADCC Reporter bioassay kit(プロメガ社)により調べた。標的細胞(Raji 細胞)をCD20抗体(rituximab)で感作した(0.001～3 μg/ml, 図11)。ADCC活性の強弱は、標的細胞死(Cytotoxicity、図11 Y 軸)を最大レベルの50％誘導できる抗体濃度(EC50、図11 X 軸)で示される。EC50 値が小さいほど、ADCC 活性は強いと解釈できる。血清IgG(IVIG)を0，0.1, 1, 10 mg/ml の濃度でADCC 測定系に加えて、EC50 値を比較したところ、それぞれ、0.026, 0.032, 0.6, >2μg/mlであり、IVIG 濃度が高いほどEC50 値が上昇し、ADCC が抑制されることが示された(図11)。
2b. ADCC inhibitory (anti-inflammatory) effect of galactosyl-nonfucosylated immunoglobulins Serum IgG from which fucose has been removed has an anti-inflammatory effect, and the effect is enhanced by having galactose at the end by the following method. discovered. As a preliminary experiment, the effect of the presence of normal serum IgG (IVIG, 95% fucosylation, FIG. 10A) on ADCC was investigated using the ADCC Reporter bioassay kit (Promega). Target cells (Raji cells) were sensitized with CD20 antibody (rituximab) (0.001-3 μg/ml, Figure 11). The strength of ADCC activity is indicated by the antibody concentration (EC50, Fig. 11 X-axis) capable of inducing 50% of the maximal level of target cell death (Cytotoxicity, Fig. 11 Y-axis). It can be interpreted that the smaller the EC50 value, the stronger the ADCC activity. Serum IgG (IVIG) was added to the ADCC measurement system at concentrations of 0, 0.1, 1, and 10 mg/ml, and the EC50 values were compared. It was shown that the higher the value, the higher the EC50 value and the suppression of ADCC (Fig. 11).
次に、糖鎖改変した非フコシル化IgG(S2)、ガラクトシル非フコシル化IgG(G2)とフコシル化IgG(S2F)を0.1 mg/ml 濃度の存在下で、ADCC を測定した(図12)。EC50 値は、PBS(陰性対照)、S2F、S2、G2 存在下で、それぞれ0.023、0.028、0.12、0.3 μg/ml であり、G2 存在下で最も強い阻害作用を示した(図12)。これは相対的ADCC 活性が、100、82、19.2、7.6%に相当する。つまり、G2 はS2F やS2 と比べ、それぞれ11 倍、2.5 倍のADCC 抑制作用を発揮したといえる。従って、ガラクトシル非フコシル化IVIG を用いれば、通常のIVIG よりも少量の投与量で抗炎症効果が期待でき、更に通常のIVIG が有効でない症例に対しても抗炎症効果を発揮できる可能性がある。
Next, ADCC was measured in the presence of glycosylated nonfucosylated IgG (S2), galactosyl nonfucosylated IgG (G2) and fucosylated IgG (S2F) at a concentration of 0.1 mg/ml (Fig. 12). The EC50 values were 0.023, 0.028, 0.12 and 0.3 µg/ml in the presence of PBS (negative control), S2F, S2 and G2, respectively, showing the strongest inhibitory action in the presence of G2 (Fig. 12). This corresponds to relative ADCC activities of 100, 82, 19.2 and 7.6%. In other words, it can be said that G2 exerted an ADCC
自己免疫疾患の治療に利用できる。 It can be used to treat autoimmune diseases.
配列番号１、２：酵素 SEQ ID NO: 1, 2: enzyme
Claims (5)
α-L-フコシダーゼ (AlfC)を用いて前記N-アセチルグルコサミンに結合したフコースを除去するフコース除去工程と、
グリコシンターゼ (Endo S D233Q)を用いて、ガラクトシルグリコペプチドから調製したオキサゾリン化糖鎖(GG-Ox)を、ヒト血清IgG抗体のFc部分のアスパラギン297(Asn297)残基に結合しているN-アセチルグルコサミンに転移する転移工程と、を有することを特徴とする抗炎症性非フコシル化免疫グロブリン製剤の製造方法。 Using endoglycosidase S (Endo S) on a human serum IgG antibody, the sugar chain bound to the asparagine 297 (Asn297) residue of the Fc portion is cleaved with chitobiose core, and N-acetyl bound to the Asn297 residue is cleaved. a sugar chain removal step of removing other than fucose bound to glucosamine and the N-acetylglucosamine;
a fucose removal step of removing fucose bound to the N-acetylglucosamine using α-L-fucosidase (AlfC);
Glycosynthase (Endo S D233Q) was used to catalyze the N-glycosylation of oxazolylated sugar chains (GG-Ox) prepared from galactosyl glycopeptides to the asparagine 297 (Asn297) residue of the Fc portion of human serum IgG antibodies. and a transfer step of transferring to acetylglucosamine.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202180093960.5A CN117083082A (en) | 2021-02-19 | 2021-03-04 | Anti-inflammatory afucosylated immunoglobulin formulations and methods of producing the same |
| PCT/JP2021/008404 WO2022176219A1 (en) | 2021-02-19 | 2021-03-04 | Anti-inflammatory, non-fucosylated immunoglobulin preparation and production method therefor |
| IL305222A IL305222A (en) | 2021-02-19 | 2021-03-04 | Anti-Inflammatory Afucosylated Immunoglobulin Preparation and Method of Producing Such |
| AU2021427938A AU2021427938A1 (en) | 2021-02-19 | 2021-03-04 | Anti-inflammatory, non-fucosylated immunoglobulin preparation and production method therefor |
| KR1020237031773A KR20230156355A (en) | 2021-02-19 | 2021-03-04 | Anti-inflammatory nonfucosylated immunoglobulin preparations and methods for producing the same |
| CA3211392A CA3211392A1 (en) | 2021-02-19 | 2021-03-04 | Anti-inflammatory afucosylated immunoglobulin preparation and method of producing such |
| BR112023016723A BR112023016723A2 (en) | 2021-02-19 | 2021-03-04 | PREPARATION OF ANTI-INFLAMMATORY AFUCOSYLATED IMMUNOGLOBULIN, AND METHOD OF PRODUCING AN ANTI-INFLAMMATORY AFUCOSYLATED IMMUNOGLOBULIN PREPARATION |
| EP21926648.3A EP4295863A1 (en) | 2021-02-19 | 2021-03-04 | Anti-inflammatory, non-fucosylated immunoglobulin preparation and production method therefor |
| JP2021527064A JP7230199B2 (en) | 2021-02-19 | 2021-03-04 | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019161306 | 2019-09-04 | ||
| JP2019161306 | 2019-09-04 | ||
| JP2020127031A JP2021042195A (en) | 2019-09-04 | 2020-07-28 | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127031A Division JP2021042195A (en) | 2019-09-04 | 2020-07-28 | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022132706A true JP2022132706A (en) | 2022-09-13 |
Family
ID=74862940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127031A Pending JP2021042195A (en) | 2019-09-04 | 2020-07-28 | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same |
| JP2021024790A Withdrawn JP2022132706A (en) | 2019-09-04 | 2021-02-19 | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127031A Pending JP2021042195A (en) | 2019-09-04 | 2020-07-28 | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP2021042195A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022176219A1 (en) * | 2021-02-19 | 2022-08-25 |
-
2020
- 2020-07-28 JP JP2020127031A patent/JP2021042195A/en active Pending
-
2021
- 2021-02-19 JP JP2021024790A patent/JP2022132706A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022176219A1 (en) * | 2021-02-19 | 2022-08-25 | ||
| JP7230199B2 (en) | 2021-02-19 | 2023-02-28 | 雄輔 三村 | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021042195A (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7374275B2 (en) | Subcutaneous preparation of anti-CD38 antibody and its use | |
| Ahmed et al. | Structural characterization of anti-inflammatory immunoglobulin G Fc proteins | |
| Goulabchand et al. | Impact of autoantibody glycosylation in autoimmune diseases | |
| US20190100573A1 (en) | Methods for modifying human antibodies by glycan engineering | |
| JP5990701B2 (en) | Therapeutic canine immunoglobulin and method of using the same | |
| JP2011506476A (en) | Polypeptides with enhanced anti-inflammatory properties and reduced cytotoxicity and related methods | |
| US20240132608A1 (en) | Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody | |
| TWI727883B (en) | Endoglycosidase mutants for glycoprotein remodeling and methods of using it | |
| JP2022132706A (en) | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same | |
| US20210353752A1 (en) | Treatment with highly silylated igg compositions | |
| Mimura et al. | Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation | |
| JP7230199B2 (en) | Anti-inflammatory non-fucosylated immunoglobulin preparation and method for producing the same | |
| JP2010512306A (en) | Polypeptides with enhanced anti-inflammatory properties and reduced cytotoxic properties and related methods | |
| WO2019175605A1 (en) | Chimeric fc receptor binding proteins and uses thereof | |
| Wang et al. | Structural and functional characterization of glycosylation in an immunoglobulin G1 to Cryptococcus neoformans glucuronoxylomannan | |
| WO2021119234A1 (en) | Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof | |
| WO2013172379A1 (en) | Novel antibody and application thereof | |
| JP2005509595A (en) | Binding agent with differential activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210301 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210301 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20221115 |